Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKP80T
|
|||
| Drug Name |
Garetosmab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Fibrodysplasia ossificans progressiva [ICD-11: FB31.1; ICD-10: M61.1] | Phase 3 | [1] | |
| Company |
Regeneron Pharmaceuticals Tarrytown, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inhibin beta A chain (INHBA) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05394116) Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva. U.S.National Institutes of Health. | |||
| REF 2 | Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. J Clin Pharmacol. 2020 Nov;60(11):1424-1431. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.